# 1 The decline of COVID-19 severity and lethality over two years of

### 2 pandemic

- 3 Valentina Marziano<sup>1</sup>, Giorgio Guzzetta<sup>1</sup>, Francesco Menegale<sup>1,2</sup>, Chiara Sacco<sup>3</sup>, Daniele Petrone<sup>3</sup>,
- 4 Alberto Mateo Urdiales<sup>3</sup>, Martina Del Manso<sup>3</sup>, Antonino Bella<sup>3</sup>, Massimo Fabiani<sup>3</sup>, Maria Fenicia
- 5 Vescio<sup>3</sup>, Flavia Riccardo<sup>3</sup>, Piero Poletti<sup>1</sup>, Mattia Manica<sup>1</sup>, Agnese Zardini<sup>1</sup>, Valeria d'Andrea<sup>1</sup>, Filippo
- 6 Trentini <sup>1,4,5</sup>, Paola Stefanelli <sup>3</sup>, Giovanni Rezza <sup>6</sup>, Anna Teresa Palamara <sup>3</sup>, Silvio Brusaferro <sup>3</sup>, Marco
- 7 Ajelli <sup>7,#</sup>, Patrizio Pezzotti <sup>3,#</sup>, Stefano Merler <sup>1,#,\*</sup>
- 8  $^{1}$  Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
- 9 <sup>2</sup> Department of Mathematics, University of Trento, Trento, Italy
- 10  $^{3}$  Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
- <sup>4</sup> Dondena Centre for Research on Social Dynamics and Public Policy, Bocconi University, Milan, Italy
- 12 <sup>5</sup> Covid Crisis Lab, Bocconi University, Italy
- 13 <sup>6</sup> Health Prevention directorate, Ministry of Health, Rome, Italy
- 14 <sup>7</sup> Laboratory for Computational Epidemiology and Public Health, Department of Epidemiology and
- 15 Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA
- 16

17 # Senior authors

- 18 \* Corresponding author: merler@fbk.eu
- 19

### 20 Abstract

- 21 Undernotification of SARS-CoV-2 infections has been a major obstacle to the tracking of critical
- 22 quantities such as infection attack rates and the probability of severe and lethal outcomes. We use a
- 23 model of SARS-CoV-2 transmission and vaccination informed by epidemiological and genomic
- surveillance data to estimate the number of daily infections occurred in Italy in the first two years of
- 25 pandemic. We estimate that the attack rate of ancestral lineages, Alpha, and Delta were in a similar
- range (10-17%, range of 95% CI: 7-23%), while that of Omicron until February 20, 2022, was
- 27 remarkably higher (51%, 95%CI: 33-70%). The combined effect of vaccination, immunity from natural
- 28 infection, change in variant features, and improved patient management massively reduced
- 29 the probabilities of hospitalization, admission to intensive care, and death given infection, with 20 to
- 30 40-fold reductions during the period of dominance of Omicron compared to the initial acute phase.
- 31 32

## 33 Introduction

- 34 The first two years of the COVID-19 pandemic have been characterized by an ever-changing
- 35 epidemiological situation, forcing almost every country in the world to face a series of major
- 36 challenges (1). During the first pandemic year, non-pharmaceutical interventions (NPIs) were widely
- 37 adopted to counter the spread of COVID-19 and prevent health care systems to be overwhelmed,
- 38 including social distancing restrictions culminating in nation-wide lockdowns, school closures and
- 39 mandatory face masks (2–6). In Europe, the second pandemic year was characterized by a progressive
- 40 relaxation of restrictions, the rollout of COVID-19 vaccination campaigns (7), and, concurrently, by the
- 41 emergence of hyper transmissible SARS-CoV-2 variants of concern (8–11).
- 42 One of the main obstacles to pandemic containment has been represented by underreported and
- 43 underdiagnosed SARS-CoV-2 infections. Due to the unknown extent of unobserved SARS-CoV-2
- 44 transmission, many aspects of the temporal changes in the COVID-19 epidemiology over the course of
- 45 the pandemic remain unclear. Infection ascertainment ratios likely changed over time due to several
- 46 fuoter susplement leading provement in the ting expectited by percessing availability of ediagona tios day statice.

47 (also sustained by the development of quicker and cheaper antigen-based detection technologies),

- 48 the varying intensity of contact-tracing, the shift of infections towards segments of the population
- 49 less likely to develop symptoms, differences in pathogenicity associated with SARS-CoV-2 variants, the
- 50 impact of external regulations (e.g. the requirement of a negative test result for access to workplaces
- or community indoor spaces in absence of vaccination), and changes in the people's attitudes and
   behavior related to SARS-CoV-2 testing or in the self-perception of symptoms associated with COVID-
- behavior related to SARS-CoV-2 testing or in the self-perception of symptoms associated with COVID 19. The quantification of changes in population susceptibility to SARS-CoV-2 infection is instrumental
- 54 to assess the expected impact of further epidemic waves. This has been a difficult task due to the lack
- 55 of knowledge on the number of undetected infections throughout the pandemic; to the partial
- 56 protection against infection provided by existing vaccines (12–14); to the emergence of new variants
- 57 partially escaping immunity from natural infection with previous lineages (15); and to the effect of
- 58 waning of protection from both natural infection and vaccination (12–14,16). If the actual number of
- 59 SARS-CoV-2 infections is unknown, it is also not possible to estimate changes in the proportion of
- 60 infections resulting in adverse outcomes (e.g., severe disease or death). In turn, these changes were
- 61 induced by COVID-19 vaccines, which have proven highly effective in preventing severe COVID-19 or
- 62 death (12,17,18), as well as by the improvement in timely diagnoses and clinical care, by the
- 63 increased health care capacity, and possibly also by changes in virulence of emerging SARS-COV-2
- 64 variants (19,20). An assessment of the immunity accrued in the first two pandemic years and of the
- 65 probability of adverse outcomes is essential to quantify the risks associated to SARS-CoV-2 infection
- 66 and COVID-19 burden in the future.
- 67 In this study, we use a mathematical model of SARS-CoV-2 transmission, informed with integrated
- 68 surveillance data (epidemiological and microbiological results on variants), to quantify the evolution
- 69 of COVID-19 epidemiology in Italy over the first two years of the pandemic. Specifically, we provide
- 70 estimates of changes in infection ascertainment ratios, infection attack rates, population susceptibility
- 71 to infection, and probability of adverse outcomes given SARS-CoV-2 infection.

#### 72 Results

73 We developed an age-structured stochastic model to simulate SARS-CoV-2 transmission and 74 vaccination in Italy between February 21, 2020, (when the first locally transmitted case was detected) 75 and February 20, 2022. We divided the two years of simulation into five phases (background colors in 76 Figure 1a). The first two phases are associated with the circulation of ancestral SARS-CoV-2 lineages 77 and they distinguish the first pandemic wave including the national lockdown (phase 1, from February 78 21, 2020 to the end of June 2020), and a second phase characterized by a new upsurge of cases in fall 79 2020 and by the start of the COVID-19 vaccination campaign on December 27, 2020 (phase 2, from 80 July 1, 2020 to February 17, 2021). The three remaining phases correspond to the periods of 81 dominance in Italy of different SARS-CoV-2 variants: Alpha (phase 3, from February 18, 2021 to July 1, 82 2021), Delta (phase 4, from July 2, 2021 to December 23, 2021), and Omicron (phase 5, from 83 December 24, 2021 to February 20, 2022) (21). The epidemic curve over the study period (Figure 1a) 84 was reproduced by adjusting the SARS-CoV-2 transmission rate on a given day in such a way that the 85 model reproduction number matches the daily net reproduction number Rt as estimated from the 86 epidemiological surveillance data (29,30). The model keeps into account the dynamics of age-specific 87 population immunity due to natural infection, to the progress of the vaccination campaign including 88 first, second and booster doses (Figure 1b) (22). The model considers waning of immunity after 89 natural infection with all lineages (16), as well as the ability of the omicron variant to escape immune 90 response from natural infection with previous SARS-CoV-2 lineages (15). Vaccine protection is 91 assumed to be "leaky", i.e. successfully vaccinated individuals are partially immune with a relative risk 92 of infection that depends on the SARS-CoV-2 variant and on the number of doses received and on the 93 time since vaccination to reproduce the effect of waning immunity (12–14). Further details on the

94 model are provided in Section Methods and in Appendix.





108 all individuals aged 12 years or more.

#### 109 Attack rate and ascertainment of SARS-CoV-2 infections

110 Despite the explosive spread of SARS-CoV-2 in the early phase of the pandemic, which threatened to

111 overwhelm the Italian health system, we estimate that the adoption of a strict nationwide lockdown

managed to limit the infection attack rate in the first phase to 2.8% (95%CI: 1.8-3.6) (Figure 2a).

113 During the second phase, in the context of less stringent NPIs, we estimate an attack rate of 11.4%

114 (95%CI: 7.3-15.2). In both phases dominated by ancestral lineages, the SARS-CoV-2 attack rate was

substantially homogeneous across age groups (Figure 2a). We estimate that in the first phase, about

116 15.0% (95%CI: 11.1-22.5) of infections, i.e. about 1 in 7, were detected by the Italian Integrated
 117 Surveillance System (Figure 2b). Even though the second phase was characterized by a greater

118 infection incidence, we estimate a higher infection ascertainment ratio of 38.6% (95%CI: 28.1-58.5)

119 (Figure 2b).

95

120 By mid-February 2021, the ancestral SARS-CoV-2 lineages were replaced by the more transmissible

121 Alpha variant (8) which remained dominant until early July 2021. During this period, we estimate that

122 Alpha infected about 10.1% (95%CI: 7.1-13.0) of the Italian population, with a marked heterogeneity

across ages: the highest attack rate is estimated in the age group 0-19 years (16.4%, 95%CI: 12.3-

124 20.1), while the lowest in people aged over 80 years (3.7%, 95%CI: 2.4-5.1) who had been prioritized

125 for vaccination in the early months of 2021 (Figure 2a and Figure S2). We estimate for this period an

126 infection ascertainment ratio of 24.9% (95%CI: 18.9-34.6) (Figure 2b).

127 The second half of 2021 was characterized by the circulation of the Delta variant, in the context of a

128 progressive relaxation of NPIs, with an estimated attack rate of 17.3% (95%CI: 11.4-23.4). Our results

129 suggest that the progression of the vaccination campaign, including the administration of booster

130 doses (Figure 1b), led to a further shift of infections towards less protected age groups (children and

131 young adults), with over one third of infections occurring among individuals aged 20 years or less

132 (Figure S4). For this period, we estimate a further decrease in the infection ascertainment ratio with

133 respect to the Alpha phase, 13.6% (95%CI: 9.7-19.9) (Figure 2b).

- 134 By the end of December 2021, the Delta variant was replaced by Omicron. We estimate that, as of
- February 20, 2022, about 51.1% (95%CI: 32.8-69.6) of the Italian population got infected with
- 136 Omicron, with age-specific attack rates ranging from 28.5% (95%CI: 15.0-46.5) in the individuals aged
- 137 80 years or more to 67.2% (95%CI: 51.8-80.7) in those younger than 20 years. For this period, we
- estimate an infection ascertainment ratio of 23.1% (95%CI: 16.4-34.7).



**Figure 2. SARS-CoV-2 attack rates and infection ascertainment ratios. a** Estimated phase-specific SARS-CoV-2

infection attack rate (%) as of February 20, 2022, in the overall population and by age classes. Colors indicate
 the considered phase. Bars: mean estimates; vertical lines: 95% CI; n=300 stochastic model realizations. b

the considered phase. Bars: mean estimates; vertical lines: 95% CI; n=300 stochastic model realizations. b
 Estimated SARS-CoV-2 infection ascertainment ratio in the different phases (%). Bars: mean estimates; vertical

144 lines: 95% CI; n=300 stochastic model realizations. The infection ascertainment ratio in each phase is estimated

145 as the fraction between the number of SARS-CoV-2 confirmed infections as reported to the Italian Integrated

146 Surveillance System and the number of infections estimated through the model in each phase.

#### 147 Evolution of population susceptibility

139

148 Throughout the first two years of the COVID-19 pandemic, the percentage of the population

149 susceptible to SARS-CoV-2 infection (depicted in shades of grey in Figure 3a) progressively decreased

150 from 97.5% (95%CI 96.8-98.4) at the end of the first phase to 13.0% (95%CI: 5.1-23.5) by February 20,

151 2022. The effect of vaccination on population susceptibility was still negligible when the ancestral

strain was replaced by the Alpha variant, with only 2.9% (95%CI: 2.8-3.0) of the population being

153 protected by vaccination (orange in Figure 3a and 3c), while it had become significant at the end of

154 the Alpha phase (Figure 3d): according to our estimates, only about one third of the population

155 (33.0%, 95%CI: 30.4-35.6) was unprotected against SARS-CoV-2 infection by July 2021, most of them

- 156 being children and young adults (Figure 3a and 3d).
- 157 The Delta phase was characterized by an increased vaccination coverage in children and young adults
- and by the start of the booster dose campaign, which initially targeted the over 80 population and
- 159 then was gradually extended to younger age groups (Figure 3e). The administration of boosters
- 160 partially compensated the waning of immunity after two doses of vaccine. However, by the end of
- 161 December 2021, when Delta was replaced by Omicron, individuals unprotected against SARS-CoV-2
- 162 infection still represented 26.6% (95%CI: 21.1-32.4) of the Italian population (Figure 3a).
- 163 We estimate that by February 20, 2022, 68.3% (95%CI: 48.6-84.3) of the Italian population was
- 164 protected by natural immunity (blue tones in Figure 3a and 3f) mostly acquired after infection with
- 165 Omicron (48.7%, 95%CI: 31.4-65.9). This percentage includes also individuals vaccinated before or
- after natural infection with SARS-CoV-2. Vaccination alone protected an additional 18.7% (95%CI:
- 167 10.7-27.9), mainly thanks to the administration of boosters (orange and red in Figure 3f). However,
- 168 we estimate that by February 20, 2022, a marked proportion of individuals unprotected against SARS-
- 169 CoV-2 infection can be found among vaccinated subjects (especially among the adults and elderly)
- 170 due to the waning of vaccine protection (dark grey in Figure 3f). At that time, the contribution of

- 171 unvaccinated individuals to residual population susceptibility was negligible (2.7% of the population,
- 172 95%CI: 0.9-5.7), with a large majority represented by children younger than 10 years.
- 173

174



175 Figure 3. SARS-CoV-2 susceptibility profiles. a Mean estimates for the overall SARS-CoV-2 susceptibility profile 176 of the Italian population at the end of each phase (n=300 stochastic model realizations). In categories 177 "protection from natural infection" the indicated variant corresponds to that of the most recent infection, 178 independently of whether the individual has been vaccinated before or after natural infection. Uninfected and 179 vaccinated individuals whose immunity has not waned are included in the "protection from vaccination" 180 categories, depending on whether they received or not a booster dose. Individuals who were never infected or 181 whose immunity against infection (from natural infection or vaccine) has waned are considered in the 182 "susceptible" categories depending on their vaccination status. Note that the latter may retain a residual 183 protection against other clinical endpoints, such as symptoms, severe disease, or death. Also note that 184 individuals who experienced SARS-CoV-2 infection (depicted in shades of blue) are considered fully protected 185 against reinfection during the ancestral, Alpha and Delta phases, while in the Omicron phase they may get 186 infected due to the significant ability of this variant to escape previous immunity from natural infection. **b** Mean 187 estimates of the SARS-CoV-2 susceptibility profile by age groups at the end of the first ancestral phase (June 30,

- 188 2020). c As b but at the end of the second ancestral phase (February 17, 2021). d As b but at the end of the
  189 Alpha phase (July 1, 2021). e As b but at the end of the Delta phase (December 23, 2021). f As b but at the end
- 190 of simulations (February 20, 2022, Omicron phase).

#### 191 Evolution of COVID-19 severity and lethality

- 192 We estimated the probability of hospitalization, admission to ICU, and death after SARS-CoV-2
- 193 infection in the different epidemic phases (Figure 4, first row). The first ancestral phase was
- 194 characterized by the highest probability of severe clinical outcomes, with a probability of
- hospitalization per infection of 5.4% (95%CI: 4.0-8.2), a probability of ICU admission of 0.65% (95%CI:
- 196 0.48-0.97) and a probability of death of 2.2% (95%CI: 1.7-3.4). Estimates of all these probabilities
- 197 progressively decreased throughout the pandemic.

- 198 The probability of hospitalization given infection is estimated to decrease to 3.1% (95%CI: 2.3-4.7) in
- the second ancestral phase (42.1% reduction compared to first ancestral phase), 2.0% (95%CI: 1.5-
- 200 2.8) in the Alpha phase (62.8% reduction compared to first ancestral phase; 35.8% compared to
- second ancestral phase), 0.56% (95%CI: 0.40-0.82) in the Delta phase (89.5% reduction compared to
- first ancestral phase; 71.9% compared to Alpha phase) and 0.27% (95%CI: 0.19-0.40) in the Omicron
- 203 phase (95.1% reduction compared to first ancestral phase and 52.7% compared to Delta phase) 204 (Figure 4a and 4d)
- 204 (Figure 4a and 4d).
- 205 The probability of ICU admission given infection is estimated to decrease to 0.45% (95%CI: 0.33-0.68)
- in the second ancestral phase (30.6% reduction compared to first ancestral phase), to 0.28% (95%CI:
- 207 0.22-0.40) in the Alpha phase (55.5% reduction compared to first ancestral phase; 35.9% compared to
- second ancestral phase), to 0.06% (95%CI: 0.04-0.09) in the Delta phase (90.7% reduction compared
- to first ancestral phase and 79.2% compared to Alpha phase) and to 0.018% (95%CI: 0.012-0.026) in
- the Omicron phase (97.3% reduction compared to first ancestral phase and 70.3% compared to Delta phase) (Figure 4b and 4e).
- Finally, we estimate the probability of death given infection at 1.0% (95%CI: 0.7-1.5) in the second
- ancestral phase (55.2% reduction compared to first ancestral phase), 0.44% (95%CI: 0.33-0.61) in the
- Alpha phase (80.2% reduction compared to the first ancestral phase; 55.9% compared to second
- ancestral phase), 0.1% (95%CI: 0.07-0.15) in the Delta phase (95.3% reduction compared to first
- ancestral phase; 76.3% compared to Alpha phase) and 0.05% (95%CI: 0.04-0.08) in the Omicron phase
- 217 (97.5% reduction compared to first ancestral phase; 47.3% compared to Delta phase) (Figure 4c and
- 218 4f).







- 227 Surveillance System and the estimated number of SARS-CoV-2 infections in the same phase. **d** Estimated relative
- reduction in the probability of hospitalization in the different phases compared to the first ancestral phase (%).
- e As d but for the probability of ICU admission. f As d but for the probability of death. Bars: mean estimates;
- 230 vertical lines: 95% CI; n=300 stochastic model realizations.

### 231 Discussion

- 232 In this work, we analyzed the first two years of the COVID-19 pandemic in Italy and quantified
- changes in COVID-19 epidemiological indicators, including the infection ascertainment ratio, the
- infection attack rate, the population susceptibility to SARS-CoV-2 infection, and the probabilities of
- hospitalization, ICU admission, and death, given infection.
- 236 Detection of SARS-CoV-2 infections changed throughout the pandemic. We estimated an increase in
- the infection ascertainment ratio between the two ancestral phases, likely ascribable to the
- expanding of testing capacity (Figure S5), to the strengthening of regional reporting systems and to an
- aggressive implementation of the test-track and trace strategy. In contrast, we found a reduction in
- infection ascertainment during the Alpha and Delta phases, probably related to a combination of
- factors including: the availability of home testing leading to self-diagnoses that were not notified to
- the surveillance system, the reduction in the frequency of contact tracing since 2021, and the
- significant increase of asymptomatic infections following the expansion of the vaccination program.
- 244 Indeed, vaccination brought a shift of infections towards younger age groups (Figure S4) and
- increased the proportion of breakthrough infections (Figure S6); both trends reduced the overall
- probability of having symptoms given an infection (26–28) and therefore the overall probability of
- test-seeking by unaware infected individuals. In the Omicron phase, we estimated that the infection
- ascertainment ratio increased again. This period was characterized by a substantial scale-up of COVID-
- 249 19 testing capacity (Figure S5) associated to the escalation of cases, as well as by a surge in voluntary
- testing in preparation for gatherings during Christmas and New Year's holidays.
- 251 We estimated that the SARS-CoV-2 infection attack rate was highest for the Delta (17%) and Omicron
- 252 (51%) phases, despite the highest vaccination coverage in the population. The large number of
- infections in these periods may be ascribable to several factors, such as a possible decline in
- adherence to residual COVID-19 restrictions due to pandemic fatigue (29); the high transmissibility of
- these variants (8–10,30); the reduced efficacy of the vaccine in preventing infection by different viral
- variants (12–14); the increased risk of reinfection during the Omicron phase compared with previous
- epidemic phases (31); the progressive release of restrictions, sustained by a lower morbidity among
- vaccinated individuals (27,28) and by a reduced intrinsic severity of Omicron (19,20).
- 259 Our results underline the key role played by booster vaccination during the Omicron phase. We
- estimated that, by the end of February 2022, about 9 out of 10 individuals in Italy who were still
- 261 protected by vaccination had received a booster dose (Figure 3a). Given the available evidence on the
- declining effectiveness of boosters over time (13,14), waning immunity will likely contribute to an
- 263 increase in population susceptibility throughout 2022 (Figure S7).
- 264 Estimates obtained for the probabilities of hospitalization, ICU admission and death given infection in
- the first phase of the pandemic (5.4%, 0.65% and 2.2%, respectively) are in line with values reported
- in the literature (32–34). We found that the severity of SARS-CoV-2 infections has progressively
   declined throughout the pandemic, with the infection fatality ratio in 2022 falling close to the levels of
- 268 2009 H1N1 pandemic influenza (estimated at about 0.02% (35)). Compared to the first pandemic
- wave, we estimated a 20 times lower probability of hospitalization, a 36 times lower probability of ICU
- admission, and a 40 times lower probability of death during the Omicron phase. The estimated
- reduction in COVID-19 severity is attributable to a combination of factors. Improved knowledge on
- the pathogen and patient management, and the relieving of the pressure on the health care system
- allowed by the national lockdown likely reduced severity between the first and second ancestral
- 274 phases. From the Alpha phase on, the vaccination program increased the population immunity

against severe disease. The predominance of Omicron variant likely contributed to a reduced severity
of the disease due to a decrease in the intrinsic viral pathogenicity (19,20). In the absence of
immunity from natural infection and vaccination the health impact of SARS-CoV-2 variants could have
been different. We note however that, as of June 2022, the overall COVID-19 morbidity and mortality
is still remarkably high in Italy due to the very high incidence of infections (25). For what concerns the
estimated probability of ICU admission given infection, we note that this does not necessarily
represent the probability of critical disease but includes the effect of patient management choices

- concerning trade-offs between the usage of limited ICU resources and the expected benefits for the
- patient; the expansion of ICU capacity throughout the pandemic may have influenced temporalchanges in this parameter.
- The proposed model was designed to evaluate overall changes of several COVID-19 epidemiological indicators at the national level, but it cannot estimate the relative weight of individual determinants
- in the reduction of the severity of SARS-CoV-2 infections. Estimates for COVID-19 severity rely on the
- assumption of negligible underdiagnosis of COVID-19 hospitalizations, admission to ICUs, and deaths.
- Another limitation of our analysis is that we consider conventionally defined epidemic phases with
- instantaneous transitions, roughly corresponding to the times at which different variants becamedominant (Table S1). The susceptibility profile of the population is also updated instantaneously at
- dominant (Table S1). The susceptibility profile of the population is also updated instantaneously at
   every change of variant, to consider different vaccination effectiveness and rates of waning. This
- every change of variant, to consider different vaccination effectiveness and rates of waning. This
   approximation is in contrast with the observation that SARS-CoV-2 variants showed extended periods
- of co-circulation (21), which are not explicitly modeled. Furthermore, we could not consider changes
- in the age-specific proportion of contacts over time in absence of longitudinal contact patterns data
- by age. This is obviously a simplification as, for example, some restrictions targeted preferentially
- 297 contacts in specific age groups (e.g., school closure). Despite these conservative assumptions, we
- show that the model approximates well age-specific trends in SARS-CoV-2 infection dynamics (FigureS4).
- 300 Quantitative estimates provided in this study apply to the case of Italy and depend on many country-
- 301 specific factors, such as governmental choices on mitigation measures, the speed of rollout of COVID-
- 302 19 vaccines, or the population socio-demographic structure. Therefore, generalization to different
- 303 geographic contexts and conditions should be made with caution. Nonetheless, we expect that the
- 304 general trends and conclusions may apply to other high-income countries that have adopted a similar
- 305 mitigation approach throughout the pandemic. In particular, considering that the Italian demographic
- 306 structure is skewed towards older ages, the decreasing trends in probabilities of adverse outcomes
- 307 might be even more marked in countries with younger populations.
- 308 Despite the large number of SARS-CoV-2 cases since the beginning of 2022, the burden of COVID-19
- in Italy has remained limited with a manageable impact on hospitals. However, the possible future
- emergence of new variants that may escape previous immunity (natural or from vaccine), be more
- transmissible and/or pathogenic stresses the need of maintaining careful surveillance on SARS-CoV-2
- variants (36) and epidemic trends. Moreover, our results highlight the key role played by the changing
- 313 immunity against SARS-CoV-2 from natural infections and vaccination on the decrease of severe
- 314 clinical outcomes upon SARS-CoV-2 infection across the different phases. This trend might be
- reversed if the level of population susceptibility to SARS-CoV-2 infection will increase again in the
- 316 future, due to waning of vaccine and natural protection.
- 317 Methods
- 318 We developed an age-structured stochastic model of SARS-CoV-2 transmission and vaccination, based
- 319 on a susceptible-infectious-removed-susceptible (SIRS) scheme (37,38). The model was used to
- 320 simulate the evolution of COVID-19 epidemiology in Italy between February 21, 2020, and February
- 321 20, 2022. The simulation period is conventionally subdivided as follows:
- 322 1. "ancestral (phase 1)", from February 21 to June 30, 2020.
- 323 2. "ancestral (phase 2)", from July 1, 2020, to February 17, 2021.

- 324 3. "Alpha (phase 3)", from February 18 to July 1, 2021.
- 325 4. "Delta (phase 4)", from July 2 to December 23, 2021.
- 326 5. "Omicron (phase 5)", from December 24, 2021 to February 20, 2022.

327 Dates of transition between variants were chosen based on estimates of the prevalence of SARS-CoV-328 2 lineages from genomic surveillance data in Italy (Table S1) (21). The model population is stratified by

- 329 age (17 5-year age groups from 0 to 84 years plus one age group for individuals aged 85 years or
- 330 older). Mixing patterns across ages are encoded by a social contact matrix estimated prior to the
- 331 COVID-19 pandemic (39). During circulation of ancestral lineages susceptibility to SARS-CoV-2
- 332 infection was assumed to be age-dependent (lower in children under 15 years of age and higher for
- 333 the elderly above 65 years, compared to individuals aged 15 to 64 years) (40). For SARS-CoV-2
- 334 variants, we assumed homogenous susceptibility across ages in absence of age-specific estimates.
- 335 Infectiousness was assumed to be homogeneous by age for all lineages (40,41).
- 336 To reproduce the epidemic curve over the study period, we adjusted the SARS-CoV-2 transmission
- 337 rate on a given day, in such a way that the model's reproduction number (estimated via the Next
- 338 Generation Matrix approach (42,43)) would match the daily net reproduction number Rt as estimated
- 339 from surveillance data (specifically, the number of new symptomatic SARS-CoV-2 infected individuals
- 340 by date of symptom onset) (29,30).
- 341 The rollout of the vaccination campaign is modeled using detailed data on the daily age-specific
- 342 number of doses administered over the considered period, including first, second and booster doses.
- 343 In the model, individuals are considered eligible for vaccination, independently of a previous SARS-
- 344 CoV-2 infection. Breakthrough infections (i.e., infections in vaccinated individuals) are assumed to be
- 345 half as infectious as those in unvaccinated individuals (44,45).
- 346 Protection from natural immune response is assumed to wane exponentially with a constant rate over
- 347 all periods considered (16). Before waning, natural infection provides complete protection against re-
- 348 infection with ancestral lineages and Alpha and Delta variants, while we assume a partial cross-
- 349 protection against Omicron (15). Waning of protection from vaccine-induced immune response was
- 350 observed only in the Delta and Omicron phases (12–14). Accordingly, we consider variant-specific
- 351 average durations of protection after two doses of vaccine and after a booster dose. Before waning of
- 352 vaccine-induced immunity, individuals are in a compartment where the risk of infection is reduced by
- 353 the vaccine efficacy. After waning of immunity either from natural infection or vaccination, individuals 354
- are in a compartment where the risk of infection is the same as unvaccinated individuals who were
- 355 never exposed to SARS-CoV-2. We note that individuals with waned protection against infection may 356
- still be protected against other clinical endpoints, such as symptoms, severe disease, or death (12).
- 357 The age-profile of SARS-CoV-2 susceptibility in the Italian population at the end of each phase is
- 358 obtained from model states variables, considering the protection acquired from natural infection or
- 359 vaccination and accounting for waning of both. The SARS-CoV-2 infection ascertainment ratio is
- 360 computed as the ratio between COVID-19 cases reported to the Italian Integrated Surveillance System
- 361 (24) and the number of SARS-CoV-2 infections estimated by the model in the same period. The
- 362 probabilities of hospitalization, ICU admission and death after SARS-CoV-2 infection are computed as
- 363 the ratio between COVID-19 cases reported to the Italian Integrated Surveillance System (24) who
- 364 were respectively admitted to hospital, ICUs, and deceased, and the number of SARS-CoV-2 infections
- 365 estimated by the model in the same period. COVID-19 cases are assigned to each period based on
- 366 their date of diagnosis. Further details on the model and parameter values are provided in Appendix.

#### 367 Data availability

- 368 Processed data and code will be made available in a public repository upon publication.
- 369

#### 370 References

- Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2.
   Science. 2022 Mar 11;375(6585):1116–21.
- Guzzetta G, Riccardo F, Marziano V, Poletti P, Trentini F, Bella A, et al. Impact of a Nationwide
   Lockdown on SARS-CoV-2 Transmissibility, Italy. Emerg Infect Dis. 2020/10/20 ed. 2021
   Jan;27(1):267–70.
- Pan A, Liu L, Wang C, Guo H, Hao X, Wang Q, et al. Association of Public Health Interventions With
   the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA. 2020 May 19;323(19):1915–
   23.
- Di Domenico L, Pullano G, Sabbatini CE, Boëlle PY, Colizza V. Impact of lockdown on COVID-19
   epidemic in Île-de-France and possible exit strategies. BMC Med. 2020 Jul 30;18(1):240.
- Coletti P, Libin P, Petrof O, Willem L, Abrams S, Herzog SA, et al. A data-driven metapopulation
   model for the Belgian COVID-19 epidemic: assessing the impact of lockdown and exit strategies.
   BMC Infect Dis. 2021 May 30;21(1):503.
- 384 6. Marziano V, Guzzetta G, Rondinone BM, Boccuni F, Riccardo F, Bella A, et al. Retrospective
  385 analysis of the Italian exit strategy from COVID-19 lockdown. Proc Natl Acad Sci. 2021 Jan
  386 26;118(4):e2019617118.
- 387 7. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID388 19 vaccinations. Nat Hum Behav. 2021 Jul;5(7):947–53.
- Stefanelli P, Trentini F, Guzzetta G, Marziano V, Mammone A, Schepisi MS, et al. Co-circulation of
   SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. Eurosurveillance. 2022
   Feb 3;27(5):2100429.
- Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
   transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021/03/03 ed.
   2021 Apr 9;372(6538):eabg3055.
- 395 10. Alizon S, Haim-Boukobza S, Foulongne V, Verdurme L, Trombert-Paolantoni S, Lecorche E, et al.
  396 Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021.
  397 Eurosurveillance. 2021 Jul 15;26(28):2100573.
- 398 11. Ferguson NM. B.1.617.2 transmission in England: risk factors and transmission advantage. 2021
   399 Jun;14.
- 400 12. Fabiani M, Puopolo M, Morciano C, Spuri M, Alegiani SS, Filia A, et al. Effectiveness of mRNA
  401 vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during
  402 predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ. 2022 Feb
  403 10;376:e069052.
- 404 13. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 Vaccine
  405 Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med [Internet]. 2022 Mar 2 [cited
  406 2022 Apr 11]; Available from: https://doi.org/10.1056/NEJMoa2119451
- 407 14. Fabiani M, Puopolo M, Filia A, Sacco C, Mateo-Urdiales A, Spila Alegiani S, et al. Effectiveness of
   408 an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons

- 409aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in410Italy, 19 July to 12 December 2021. Expert Rev Vaccines. 2022 Apr 7;0(0):1–8.
- 411 15. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection
  412 against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022 Mar
  413 31;386(13):1288–90.
- 414 16. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of
  415 antibody-positive compared with antibody-negative health-care workers in England: a large,
  416 multicentre, prospective cohort study (SIREN). The Lancet. 2021 Apr 17;397(10283):1459–69.
- 417 17. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical severity of,
  418 and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2
  419 variants in the United States: prospective observational study. BMJ. 2022 Mar 9;376:e069761.
- 420 18. Sacco C, Mateo-Urdiales A, Petrone D, Spuri M, Fabiani M, Vescio MF, et al. Estimating averted
  421 COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19
  422 vaccination, Italy, January–September 2021. Eurosurveillance. 2021 Nov 25;26(47):2101001.
- 423 19. Bager P, Wohlfahrt J, Bhatt S, Stegger M, Legarth R, Møller CH, et al. Risk of hospitalisation
  424 associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an
  425 observational cohort study. Lancet Infect Dis [Internet]. 2022 Apr 22 [cited 2022 Apr 29];0(0).
  426 Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00154427 2/fulltext
- 428 20. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the
  429 clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The
  430 Lancet. 2022 Jan 29;399(10323):437–46.
- 431 21. Istituto Superiore di Sanità. Monitoraggio delle varianti del virus SARS-CoV-2 di interesse in sanità
  432 pubblica in Italia [Internet]. [cited 2022 Apr 22]. Available from:
  433 https://www.epicentro.iss.it/coronavirus/sars-cov-2-monitoraggio-varianti-indagini-rapide
- 434 22. Covid-19 Opendata Vaccini [Internet]. Developers Italia; 2022 [cited 2022 Apr 12]. Available from:
  435 https://github.com/italia/covid19-opendata-vaccini
- 436
  436 23. Task force COVID-19 del Dipartimento Malattie Infettive, Servizio di Informatica, Istituto
  437 Superiore di Sanità. Epidemia COVID-19. Aggiornamento nazionale: 2 marzo 2022 [Internet].
  438 Available from: https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza439 integrata-COVID-19\_2-marzo-2022.pdf
- 440 24. Riccardo F, Ajelli M, Andrianou XD, Bella A, Manso MD, Fabiani M, et al. Epidemiological
  441 characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the
  442 epidemic, Italy, 28 January to 31 March 2020. Eurosurveillance. 2020 Dec 10;25(49):2000790.
- 443 25. Istituto Superiore di Sanità. COVID-19 ISS open data EpiCentro. [Internet]. [cited 2022 Apr 19].
  444 Available from: https://www.epicentro.iss.it/coronavirus/open-data/covid\_19-iss.xlsx
- Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Sabatino G, et al. Association of Age With
  Likelihood of Developing Symptoms and Critical Disease Among Close Contacts Exposed to
  Patients With Confirmed SARS-CoV-2 Infection in Italy. JAMA Netw Open. 2021 Mar
  10;4(3):e211085.

- 27. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
  the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Nov
  4;385(19):1761–73.
- 452 28. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the
  453 mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov
  454 4;385(19):1774–85.
- Petherick A, Goldszmidt R, Andrade EB, Furst R, Hale T, Pott A, et al. A worldwide assessment of
  changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue.
  Nat Hum Behav. 2021 Sep;5(9):1145–60.
- 458 30. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased
  459 transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021.
  460 Eurosurveillance. 2021 Jun 17;26(24):2100509.
- 31. Sacco C, Petrone D, Manso MD, Mateo-Urdiales A, Fabiani M, Bressi M, et al. Risk and protective
  factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022.
  Eurosurveillance. 2022 May 19;27(20):2200372.
- 32. Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of
  SARS-CoV-2 in France. Science. 2020 Jul 10;369(6500):208–11.
- 33. Zardini A, Galli M, Tirani M, Cereda D, Manica M, Trentini F, et al. A quantitative assessment of
  epidemiological parameters required to investigate COVID-19 burden. Epidemics. 2021 Dec
  1;37:100530.
- 469 34. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al. Age-specific SARS-CoV-2
  470 infection fatality ratio and associated risk factors, Italy, February to April 2020. Eurosurveillance.
  471 2020 Aug 6;25(31):2001383.
- 472 35. Khandaker G, Dierig A, Rashid H, King C, Heron L, Booy R. Systematic review of clinical and
  473 epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respir
  474 Viruses. 2011 May 1;5(3):148–56.
- 475 36. Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new SARS-CoV-2 variants
  476 with unpredictable severity. Nat Rev Microbiol. 2022 May;20(5):251–2.
- 477 37. Yang J, Marziano V, Deng X, Guzzetta G, Zhang J, Trentini F, et al. Despite vaccination, China
  478 needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021.
  479 Nat Hum Behav. 2021 Aug 1;5(8):1009–20.
- 480 38. Marziano V, Guzzetta G, Mammone A, Riccardo F, Poletti P, Trentini F, et al. The effect of COVID481 19 vaccination in Italy and perspectives for living with the virus. Nat Commun. 2021 Dec
  482 14;12(1):7272.
- 483 39. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social Contacts and Mixing
  484 Patterns Relevant to the Spread of Infectious Diseases. PLOS Med. 2008 Mar 25;5(3):e74.
- 485 40. Hu S, Wang W, Wang Y, Litvinova M, Luo K, Ren L, et al. Infectivity, susceptibility, and risk factors
  486 associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. Nat
  487 Commun. 2021 Mar 9;12(1):1533.

- 488 41. Sun K, Wang W, Gao L, Wang Y, Luo K, Ren L, et al. Transmission heterogeneities, kinetics, and
  489 controllability of SARS-CoV-2. Science. 2021 Jan 15;371(6526):eabe2424.
- 490 42. Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of the basic
  491 reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math
  492 Biol. 1990 Jun 1;28(4):365–82.
- 493 43. Diekmann O, Heesterbeek J a. P, Roberts MG. The construction of next-generation matrices for
  494 compartmental epidemic models. J R Soc Interface. 2010 Jun 6;7(47):873–85.
- 495 44. Harris RJ, Hall JA, Zaidi A, Andrews NJ, Dunbar JK, Dabrera G. Effect of Vaccination on Household
  496 Transmission of SARS-CoV-2 in England. N Engl J Med. 2021 Aug 19;385(8):759–60.
- 497 45. Lipsitch M, Kahn R. Interpreting vaccine efficacy trial results for infection and transmission.
  498 Vaccine. 2021 Jul 5;39(30):4082–8.

499